Thinly traded nano cap Aytu BioScience (NASDAQ:AYTU) is up 9% premarket on modestly higher volume in reaction to its expanded agreement with commercialization partner Acerus Pharmaceuticals (OTCQB:ASPCF).
Aimed at stoking U.S. sales of Natesto (testosterone) nasal gel, Acerus will fund and launch a specialty salesforce of at least 25 reps that will promote the intranasal testosterone replacement therapy to urologists and endocrinologists.
Aytu will continue to book Natesto revenue and will pay Acerus quarterly commissions from sales to urologists and endocrinologists.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.